MARÍA DEL CARMEN MARTÍNEZ MORA-rekin lankidetzan egindako argitalpenak (75)

2022

  1. Human CD4+CD45RA+ T Cells Behavior after In Vitro Activation: Modulatory Role of Vasoactive Intestinal Peptide

    International Journal of Molecular Sciences, Vol. 23, Núm. 4

  2. VIP/VPAC Axis Expression in Immune-Mediated Inflammatory Disorders: Associated miRNA Signatures

    International journal of molecular sciences, Vol. 23, Núm. 15

2021

  1. Proteomic analysis of synovial fibroblasts and articular chondrocytes co-cultures reveals valuable vip-modulated inflammatory and degradative proteins in osteoarthritis

    International Journal of Molecular Sciences, Vol. 22, Núm. 12

  2. The neuropeptide vip limits human osteoclastogenesis: Clinical associations with bone metabolism markers in patients with early arthritis

    Biomedicines, Vol. 9, Núm. 12

2020

  1. A clinical approach for the use of VIP axis in inflammatory and autoimmune diseases

    International Journal of Molecular Sciences, Vol. 21, Núm. 1

  2. Comparative Study of Senescent Th Biomarkers in Healthy Donors and Early Arthritis Patients. Analysis of VPAC Receptors and Their Influence

    Cells, Vol. 9, Núm. 12

  3. Identification of a Human SOCS1 Polymorphism That Predicts Rheumatoid Arthritis Severity

    Frontiers in Immunology, Vol. 11

2019

  1. Activation of Th lymphocytes alters pattern expression and cellular location of VIP receptors in healthy donors and early arthritis patients

    Scientific Reports, Vol. 9, Núm. 1

  2. An Overview of VPAC Receptors in Rheumatoid Arthritis: Biological Role and Clinical Significance

    Frontiers in Endocrinology, Vol. 10

  3. Profile of Matrix-Remodeling Proteinases in Osteoarthritis: Impact of Fibronectin

    Cells, Vol. 9, Núm. 1

2018

  1. The anti-inflammatory mediator, vasoactive intestinal peptide, modulates the differentiation and function of Th subsets in rheumatoid arthritis

    Journal of Immunology Research, Vol. 2018

  2. Vasoactive intestinal peptide gene polymorphisms, associated with its serum levels, predict treatment requirements in early rheumatoid arthritis

    Scientific Reports, Vol. 8, Núm. 1

2016

  1. Clinical relevance of VPAC1 receptor expression in early arthritis: Association with IL-6 and disease activity

    PLoS ONE, Vol. 11, Núm. 2

  2. VIP impairs acquisition of the macrophage proinflammatory polarization profile

    Journal of Leukocyte Biology, Vol. 100, Núm. 6, pp. 1385-1393

2015

  1. Biomarkers predicting a need for intensive treatment in patients with early arthritis

    Current Pharmaceutical Design, Vol. 21, Núm. 2, pp. 170-181

  2. Th17 polarization of memory Th cells in early arthritis: The vasoactive intestinal peptide effect

    Journal of Leukocyte Biology, Vol. 98, Núm. 2, pp. 257-269

  3. Vasoactive Intestinal Peptide in Early Spondyloarthritis: Low Serum Levels as a Potential Biomarker for Disease Severity

    Journal of Molecular Neuroscience, Vol. 56, Núm. 3, pp. 577-584

2014

  1. Serum Levels of Vasoactive Intestinal Peptide as a Prognostic Marker in Early Arthritis

    PLoS ONE, Vol. 9, Núm. 1

  2. VIP modulates IL-22R1 expression and prevents the contribution of rheumatoid synovial fibroblasts to IL-22-mediated joint destruction

    Journal of Molecular Neuroscience, Vol. 52, Núm. 1, pp. 10-17

  3. Vasoactive Intestinal Peptide Maintains the Nonpathogenic Profile of Human Th17-Polarized Cells

    Journal of Molecular Neuroscience, Vol. 54, Núm. 3, pp. 512-525